Top Insights and Key Trends at ESMO Breast Cancer 2026

Berlin will host the European Society for Medical Oncology (ESMO) Breast Cancer Congress from May 6 to May 8, 2026, bringing together global experts to discuss the latest advances in breast cancer research and treatment. The event will focus on critical questions in breast oncology, including chemotherapy-sparing strategies for HER2-positive disease, the sequencing of antibody-drug conjugates (ADCs), and the role of circulating tumor DNA (ctDNA) in refining early response assessments. Among the most anticipated presentations is Late-Breaking Abstract 1 (LBA1), which will address a pressing clinical dilemma: how to manage residual disease in HER2-positive early breast cancer after neoadjuvant therapy with trastuzumab deruxtecan (T-DXd).

Key Themes at ESMO Breast Cancer 2026

The congress will explore several high-priority topics shaping the future of breast cancer care. These include:

• HER2-positive early breast cancer: Strategies to reduce or eliminate chemotherapy while maintaining efficacy, particularly in the neoadjuvant setting.
• Metastatic HER2-positive disease: The optimal sequencing of ADCs like T-DXd and the potential for combination therapies.
• ER+/HER2-negative early breast cancer: Advances in endocrine therapy and the role of selective estrogen receptor degraders (SERDs).
• Pan-subtype ADC development: Emerging data on novel ADCs and their applicability across breast cancer subtypes.
• ctDNA-guided treatment strategies: The use of liquid biopsies to monitor treatment response and guide therapeutic decisions.
• National germline testing programs: Large-scale genetic testing initiatives to inform prevention and long-term care.

These themes reflect a broader shift in breast oncology toward precision medicine, where treatment decisions are increasingly tailored to individual tumor biology and patient genetics.

Residual Disease After Neoadjuvant T-DXd: A Clinical Dilemma

One of the most clinically relevant questions at ESMO Breast Cancer 2026 will be addressed in LBA1, which examines residual cancer burden after neoadjuvant therapy with T-DXd in HER2-positive early breast cancer. The study compares two post-neoadjuvant strategies: THP (docetaxel, trastuzumab, pertuzumab) versus dose-dense AC-THP (doxorubicin, cyclophosphamide, followed by THP) in patients who still have residual disease after T-DXd-based therapy.

This question is particularly timely because T-DXd, an ADC combining a HER2-targeted antibody with a topoisomerase I inhibitor, is increasingly being studied in earlier disease settings. As clinicians integrate T-DXd into neoadjuvant regimens, they face a growing challenge: what to do when patients still have residual disease after ADC-based therapy. The post-neoadjuvant setting is already a critical decision point in HER2-positive early breast cancer, and the introduction of T-DXd adds a new layer of complexity to treatment sequencing.

LBA1 is not expected to provide definitive answers before the data are presented, but it will highlight a practical clinical scenario that is likely to become more common as ADCs move into earlier treatment lines. The findings could help shape guidelines for managing residual disease in this patient population.

Advances in ADC Sequencing and Early-Stage Treatment

Beyond LBA1, the congress will feature discussions on the optimal sequencing of ADCs in both early and metastatic HER2-positive breast cancer. T-DXd has already demonstrated significant efficacy in metastatic disease, and its potential in earlier settings is a major focus of ongoing research. Clinicians are particularly interested in whether T-DXd can replace or reduce the need for traditional chemotherapy in neoadjuvant and adjuvant regimens.

Another key area of exploration is the role of ctDNA in monitoring treatment response. Liquid biopsies, which detect tumor DNA in the bloodstream, offer a non-invasive way to assess disease burden and guide treatment adjustments. Several presentations at ESMO Breast Cancer 2026 will examine how ctDNA can be used to refine early response assessments and identify patients who may benefit from treatment escalation or de-escalation.

Germline Testing and Prevention

The congress will also highlight the growing importance of germline testing in breast cancer care. Large-scale genetic testing programs are being implemented in several countries to identify individuals at high risk of developing breast cancer due to inherited mutations, such as those in the BRCA1 and BRCA2 genes. These programs aim to improve early detection, inform prevention strategies, and guide long-term surveillance for high-risk individuals.

Presentations on germline testing will explore how these programs can be scaled and integrated into routine clinical practice, as well as their potential to reduce breast cancer incidence and mortality through targeted interventions.

What to Expect from the Congress

ESMO Breast Cancer 2026 will feature a mix of keynote lectures, educational symposia, and expert-led discussions. The program is designed to bridge the gap between research and clinical practice, offering attendees actionable insights into the latest therapeutic strategies and diagnostic tools. While the full results of the studies will not be available until the congress, the abstracts and presentations are expected to generate significant discussion among oncologists, researchers, and patient advocates.

The event will also provide a platform for networking and collaboration, with opportunities for attendees to engage with leading experts in the field. Exhibitors and sponsors will showcase the latest innovations in breast cancer diagnostics and therapeutics, further enriching the congress experience.

Why This Matters for Patients and Clinicians

The advances discussed at ESMO Breast Cancer 2026 have the potential to transform breast cancer care in several ways. For patients with HER2-positive disease, the shift toward chemotherapy-sparing strategies could reduce treatment-related side effects without compromising efficacy. For those with residual disease after neoadjuvant therapy, clearer guidance on post-treatment management could improve long-term outcomes.

For clinicians, the congress will provide critical insights into the optimal use of ADCs, the role of ctDNA in treatment monitoring, and the integration of germline testing into clinical practice. These developments are part of a broader trend toward personalized medicine, where treatment decisions are increasingly based on individual tumor characteristics and genetic profiles.

While many of the findings presented at ESMO Breast Cancer 2026 will require further validation in larger studies, the congress represents an important step forward in addressing some of the most pressing challenges in breast oncology. As the field continues to evolve, events like this play a crucial role in translating research into real-world clinical benefits.

For more information on the congress, including the full program and registration details, visit the ESMO Breast Cancer 2026 website.